A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs GSK 2256098 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 11 Oct 2016 Results published in the Annals of Oncology
- 21 Apr 2016 Status changed from recruiting to completed.
- 27 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.